(Q41103020)

26 September 2017

1 reference

title

Neutralization of HIV-1 by antibody (English)

1 reference

26 September 2017

Sattentau QJ

1

1 reference

26 September 2017

1 August 1996

1 reference

Current Opinion in Immunology

26 September 2017

1 reference

26 September 2017

8

1 reference

26 September 2017

4

1 reference

26 September 2017

540-545

1 reference

Neutralization of primary HIV-1 isolates by anti-envelope monoclonal antibodies

26 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980044-6

7 January 2021

Antibody neutralization of HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980044-6

7 January 2021

gp 120: good, bad or indifferent?

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980044-6

7 January 2021

Role of humoral factors in the progression of HIV disease

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980044-6

7 January 2021

Back to primary school

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980044-6

7 January 2021

Neutralization of HIV-1

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980044-6

7 January 2021

Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980044-6

7 January 2021

Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980044-6

7 January 2021

Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980044-6

7 January 2021

Quantitative model of antibody- and soluble CD4-mediated neutralization of primary isolates and T-cell line-adapted strains of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980044-6

7 January 2021

Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980044-6

7 January 2021

Effective ex vivo neutralization of human immunodeficiency virus type 1 in plasma by recombinant immunoglobulin molecules

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980044-6

7 January 2021

Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980044-6

7 January 2021

Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980044-6

7 January 2021

Neutralization of HIV-1 by secretory IgA induced by oral immunization with a new macromolecular multicomponent peptide vaccine candidate

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980044-6

7 January 2021

Host cell components affect the sensitivity of HIV type 1 to complement-mediated virolysis

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980044-6

7 January 2021

Macaques immunized with HLA-DR are protected from challenge with simian immunodeficiency virus.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980044-6

7 January 2021

Antibody to adhesion molecule LFA-1 enhances plasma neutralization of human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980044-6

7 January 2021

Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980044-6

7 January 2021

Structural modulations of the envelope gp120 glycoprotein of human immunodeficiency virus type 1 upon oligomerization and differential V3 loop epitope exposure of isolates displaying distinct tropism upon virion-soluble receptor binding

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980044-6

7 January 2021

Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: oligomer-specific and -sensitive monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980044-6

7 January 2021

Resistance to V3-directed neutralization caused by an N-linked oligosaccharide depends on the quaternary structure of the HIV-1 envelope oligomer

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980044-6

7 January 2021

The role of the V3 loop of gp120 in HIV infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980044-6

7 January 2021

Neutralizing antibodies to human immunodeficiency virus type-1 gp120 induce envelope glycoprotein subunit dissociation.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980044-6

7 January 2021

Direct measurement of soluble CD4 binding to human immunodeficiency virus type 1 virions: gp120 dissociation and its implications for virus-cell binding and fusion reactions and their neutralization by soluble CD4.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980044-6

7 January 2021

Enhancement of infectivity of a non-syncytium inducing HIV-1 by sCD4 and by human antibodies that neutralize syncytium inducing HIV-1

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980044-6

7 January 2021

Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980044-6

7 January 2021

Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980044-6

7 January 2021

Immune escape and tropism of HIV

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980044-6

7 January 2021

Mother-to-child transmission of human immunodeficiency virus type 1: correlation with neutralizing antibodies against primary isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980044-6

7 January 2021

Protection against HIV-1 infection in hu-PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4-binding site.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980044-6

7 January 2021

An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980044-6

7 January 2021

Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980044-6

7 January 2021

Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2896%2980044-6

7 January 2021

10.1016/S0952-7915(96)80044-6

Identifiers

DOI

1 reference

26 September 2017

1 reference

PubMed ID

8794008